A Phase I, Open-Label Study to Determine the Effect of Panitumumab on the Pharmacokinetics of Irinotecan in Subjects With Unresectable Metastatic Colorectal Cancer.

Trial Profile

A Phase I, Open-Label Study to Determine the Effect of Panitumumab on the Pharmacokinetics of Irinotecan in Subjects With Unresectable Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Apr 2016

At a glance

  • Drugs Panitumumab (Primary) ; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 11 Apr 2016 Trial focus changed: Adverse events has been added to primary endpoints.
    • 30 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Aug 2010 Planned end date changed from Nov 2010 to Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top